Factor X

For other uses, see Factor X (disambiguation).

Coagulation factor X (EC 3.4.21.6), or Stuart factor, is an enzyme of the coagulation cascade, encoded in humans by F10 gene. It is a serine endopeptidase (protease group S1, PA clan). Factor X is synthesized in the liver and requires vitamin K for its synthesis.

F10
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1C5M, 1EZQ, 1F0R, 1F0S, 1FAX, 1FJS, 1G2L, 1G2M, 1HCG, 1IOE, 1IQE, 1IQF, 1IQG, 1IQH, 1IQI, 1IQJ, 1IQK, 1IQL, 1IQM, 1IQN, 1KSN, 1LPG, 1LPK, 1LPZ, 1LQD, 1MQ5, 1MQ6, 1NFU, 1NFW, 1NFX, 1NFY, 1P0S, 1V3X, 1WU1, 1XKA, 1XKB, 1Z6E, 2BMG, 2BOH, 2BOK, 2BQ6, 2BQ7, 2BQW, 2CJI, 2D1J, 2EI6, 2EI7, 2EI8, 2FZZ, 2G00, 2GD4, 2H9E, 2J2U, 2J34, 2J38, 2J4I, 2J94, 2J95, 2JKH, 2P16, 2P3F, 2P3T, 2P3U, 2P93, 2P94, 2P95, 2PHB, 2PR3, 2Q1J, 2RA0, 2UWL, 2UWO, 2UWP, 2VH0, 2VH6, 2VVC, 2VVU, 2VVV, 2VWL, 2VWM, 2VWN, 2VWO, 2W26, 2W3I, 2W3K, 2WYG, 2WYJ, 2XBV, 2XBW, 2XBX, 2XBY, 2XC0, 2XC4, 2XC5, 2Y5F, 2Y5G, 2Y5H, 2Y7X, 2Y7Z, 2Y80, 2Y81, 2Y82, 3CEN, 3CS7, 3ENS, 3FFG, 3HPT, 3IIT, 3K9X, 3KL6, 3Q3K, 3SW2, 3TK5, 3TK6, 4A7I, 3KQB, 3KQC, 3KQD, 3KQE, 3LIW, 3M36, 3M37, 4BTI, 4BTT, 4BTU, 4Y6D, 4Y71, 4Y76, 4Y79, 4Y7A, 4Y7B, 4ZHA, 4ZH8, 5K0H
Identifiers
Aliases	F10, FX, FXA, coagulation factor X
External IDs	OMIM: 613872; MGI: 103107; HomoloGene: 30976; GeneCards: F10; OMA:F10 - orthologs
Gene location (Human) Chr. Chromosome 13 (human) Band 13q34 Start 113,122,799 bp End 113,149,529 bp
Gene location (Mouse) Chr. Chromosome 8 (mouse) Band 8 A1.1|8 5.73 cM Start 13,087,308 bp End 13,106,676 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in right lobe of liver stromal cell of endometrium right auricle canal of the cervix ectocervix gastric mucosa right ovary left ovary right coronary artery left uterine tube Top expressed in left lobe of liver yolk sac gallbladder embryo fetal liver hematopoietic progenitor cell epithelium of small intestine blood sexually immature organism granulocyte bone marrow More reference expression data BioGPS More reference expression data
Gene ontology Molecular function calcium ion binding peptidase activity protein binding serine-type peptidase activity serine-type endopeptidase activity phospholipid binding hydrolase activity Cellular component endoplasmic reticulum lumen intrinsic component of external side of plasma membrane plasma membrane extracellular region Golgi lumen extracellular space Biological process hemostasis positive regulation of protein kinase B signaling positive regulation of cell migration blood coagulation proteolysis endoplasmic reticulum to Golgi vesicle-mediated transport blood coagulation, extrinsic pathway Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 2159 14058 Ensembl ENSG00000126218 ENSMUSG00000031444 UniProt P00742 O88947 RefSeq (mRNA) NM_000504 NM_001312674 NM_001312675 NM_001242368 NM_007972 RefSeq (protein) NP_000495 NP_001299603 NP_001299604 NP_001229297 NP_031998 Location (UCSC) Chr 13: 113.12 – 113.15 Mb Chr 8: 13.09 – 13.11 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Factor X is activated, by hydrolysis, into factor Xa by both factor IX with its cofactor, factor VIII in a complex known as intrinsic pathway; and factor VII with its cofactor, tissue factor in a complex known as extrinsic pathway. It is therefore the first member of the final common pathway or thrombin pathway.

It acts by cleaving prothrombin in two places (an Arg-Thr and then an Arg-Ile bond), which yields the active thrombin. This process is optimized when factor Xa is complexed with activated co-factor V in the prothrombinase complex.

Factor Xa is inactivated by protein Z-dependent protease inhibitor (ZPI), a serine protease inhibitor (serpin). The affinity of this protein for factor Xa is increased 1000-fold by the presence of protein Z, while it does not require protein Z for inactivation of factor XI. Defects in protein Z lead to increased factor Xa activity and a propensity for thrombosis. The half life of factor X is 40–45 hours.

Structure

See also: Factor IX § Domain architecture

The first crystal structure of human factor Xa was deposited in May 1993. To date, 191 crystal structures of factor Xa with various inhibitors have been deposited in the protein data bank. The active site of factor Xa is divided into four subpockets as S1, S2, S3 and S4. The S1 subpocket determines the major component of selectivity and binding. The S2 sub-pocket is small, shallow and not well defined. It merges with the S4 subpocket. The S3 sub-pocket is located on the rim of the S1 pocket and is quite exposed to solvent. The S4 sub-pocket has three ligand binding domains: the "hydrophobic box", the "cationic hole" and the water site. Factor Xa inhibitors generally bind in an L-shaped conformation, where one group of the ligand occupies the anionic S1 pocket lined by residues Asp189, Ser195, and Tyr228, and another group of the ligand occupies the aromatic S4 pocket lined by residues Tyr99, Phe174, and Trp215. Typically, a fairly rigid linker group bridges these two interaction sites.

Genetics

The human factor X gene is located on chromosome 13 (13q34).

Role in disease

Main article: Factor X deficiency

Inborn deficiency of factor X is very rare (1:1,000,000), and may present with epistaxis (nosebleeds), hemarthrosis (bleeding into joints) and gastrointestinal blood loss. Apart from congenital deficiency, low factor X levels may occur occasionally in a number of disease states. For example, factor X deficiency may be seen in amyloidosis, where factor X is adsorbed to the amyloid fibrils in the vasculature.

Deficiency of vitamin K or antagonism by warfarin (or similar medication) leads to the production of an inactive factor X. In warfarin therapy, this is desirable to prevent thrombosis. As of late 2007, four out of five emerging anti-coagulation therapeutics _targeted this enzyme.

Inhibiting Factor Xa would offer an alternate method for anticoagulation. Direct Xa inhibitors are popular anticoagulants.

Polymorphisms in Factor X have been associated with an increased prevalence in bacterial infections, suggesting a possible role directly regulating the immune response to bacterial pathogens.

Therapeutic use

Factor X is part of fresh frozen plasma and the prothrombinase complex. There are two commercially available Factor X concentrates: "Factor X P Behring" manufactured by CSL Behring, and high purity Factor X Coagadex produced by Bio Products Laboratory and approved for use in the United States by the FDA in October 2015, and in the EU in March 2016, after earlier acceptance by CHMP and COMP.

Kcentra, manufactured by CSL Behring, is a concentrate containing coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S.

Use in biochemistry

The factor Xa protease can be used in biochemistry to cleave off protein tags that improve expression or purification of a protein of interest. Its preferred cleavage site (after the arginine in the sequence Ile-Glu/Asp-Gly-Arg, IEGR or IDGR) can easily be engineered between a tag sequence and the protein of interest. After expression and purification, the tag is then proteolytically removed by factor Xa.

Factor Xa

Blood coagulation pathways in vivo showing the central role played by thrombin

Factor Xa is the activated form of the coagulation factor X, also known as thrombokinase. Factor X is an enzyme, a serine endopeptidase, which plays a key role at several stages of the coagulation system. Factor X is synthesized in the liver. The most commonly used anticoagulants in clinical practice, warfarin and the heparin series of anticoagulants and fondaparinux, act to inhibit the action of Factor Xa in various degrees.

Traditional models of coagulation developed in the 1960s envisaged two separate cascades, the extrinsic (tissue factor (TF)) pathway and the intrinsic pathway. These pathways converge to a common point, the formation of the Factor Xa/Va complex which together with calcium and bound on a phospholipids surface, generate thrombin (Factor IIa) from prothrombin (Factor II).

A new model, the cell-based model of anticoagulation appears to explain more fully the steps in coagulation. This model has three stages: 1) initiation of coagulation on TF-bearing cells, 2) amplification of the procoagulant signal by thrombin generated on the TF-bearing cell and 3) propagation of thrombin generation on the platelet surface. Factor Xa plays a key role in all three of these stages.

In stage 1, Factor VII binds to the transmembrane protein TF on the surface of cells and is converted to Factor VIIa. The result is a Factor VIIa/TF complex, which catalyzes the activation of Factor X and Factor IX. Factor Xa formed on the surface of the TF-bearing cell interacts with Factor Va to form the prothrombinase complex which generates small amounts of thrombin on the surface of TF-bearing cells.

In stage 2, the amplification stage, if enough thrombin has been generated, then activation of platelets and platelet-associated cofactors occurs.

In stage 3, thrombin generation, Factor XIa activates free Factor IX on the surface of activated platelets. The activated Factor IXa with Factor VIIIa forms the "tenase" complex. This "tenase" complex activates more Factor X, which in turn forms new prothrombinase complexes with Factor Va. Factor Xa is the prime component of the prothrombinase complex which converts large amounts of prothrombin—the "thrombin burst". Each molecule of Factor Xa can generate 1000 molecules of thrombin. This large burst of thrombin is responsible for fibrin polymerization to form a thrombus.

Factor Xa also plays a role in other biological processes that are not directly related to coagulation, like wound healing, tissue remodelling, inflammation, angiogenesis and atherosclerosis.

Inhibition of the synthesis or activity of Factor X is the mechanism of action for many anticoagulants in use today. Warfarin, a synthetic derivative of coumarin, is the most widely used oral anticoagulant in the US. In some European countries, other coumarin derivatives (phenprocoumon and acenocoumarol) are used. These agents known as vitamin K antagonists (VKA), inhibit the vitamin K-dependent carboxylation of Factors II (prothrombin), VII, IX, X in the hepatocyte. This carboxylation after the translation is essential for the physiological activity.

Heparin (unfractionated heparin) and its derivatives low molecular weight heparin (LMWH) bind to a plasma cofactor, antithrombin (AT) to inactivate several coagulation factors IIa, Xa, XIa and XIIa. The affinity of unfractionated heparin and the various LMWHs for Factor Xa varies considerably. The efficacy of heparin-based anticoagulants increases as selectivity for Factor Xa increases. LMWH shows increased inactivation of Factor Xa compared to unfractionated heparin, and fondaparinux, an agent based on the critical pentasacharide sequence of heparin, shows more selectivity than LMWH. This inactivation of Factor Xa by heparins is termed "indirect" since it relies on the presence of AT and not a direct interaction with Factor Xa.

Recently a new series of specific, direct acting inhibitors of Factor Xa has been developed. These include the drugs rivaroxaban, apixaban, betrixaban, LY517717, darexaban (YM150), edoxaban and 813893. These agents have several theoretical advantages over current therapy. They may be given orally. They have rapid onset of action. And they may be more effective against Factor Xa in that they inhibit both free Factor Xa and Factor Xa in the prothrombinase complex.

History

American and British scientists described deficiency of factor X independently in 1953 and 1956, respectively. As with some other coagulation factors, the factor was initially named after these patients, a Mr Rufus Stuart (1921) and a Miss Audrey Prower (1934). At that time, those investigators could not know that the human genetic defect they had identified would be found in the previously characterized enzyme called thrombokinase.

Thrombokinase was the name coined by Paul Morawitz in 1904 to describe the substance that converted prothrombin to thrombin and caused blood to clot. That name embodied an important new concept in understanding blood coagulation – that an enzyme was critically important in the activation of prothrombin. Morawitz believed that his enzyme came from cells such as platelets yet, in keeping with the state of knowledge about enzymes at that time, he had no clear idea about the chemical nature of his thrombokinase or its mechanism of action. Those uncertainties led to decades during which the terms thrombokinase and thromboplastin were both used to describe the activator of prothrombin and led to controversy about its chemical nature and origin.

In 1947, J Haskell Milstone isolated a proenzyme from bovine plasma which, when activated, converted prothrombin to thrombin. Following Morawitz’s designation, he called it prothrombokinase and by 1951 had purified the active enzyme, thrombokinase. Over the next several years he showed that thrombokinase was a proteolytic enzyme that, by itself, could activate prothrombin. Its activity was greatly enhanced by addition of calcium, other serum factors, and tissue extracts, which represented the thromboplastins that promoted the conversion of prothrombin to thrombin by their interaction with thrombokinase. In 1964 Milstone summarized his work and that of others: “There are many chemical reactions which are so slow that they would not be of physiological use if they were not accelerated by enzymes. We are now confronted with a reaction, catalyzed by an enzyme, which is still too slow unless aided by accessory factors.”

Interactions

Factor X has been shown to interact with Tissue factor pathway inhibitor.

Further reading

• Cooper DN, Millar DS, Wacey A, Pemberton S, Tuddenham EG (July 1997). "Inherited factor X deficiency: molecular genetics and pathophysiology". Thrombosis and Haemostasis. 78 (1): 161–172. doi:10.1055/s-0038-1657520. PMID 9198147. S2CID 27129058.
• Hassan HJ, Leonardi A, Chelucci C, Mattia G, Macioce G, Guerriero R, et al. (September 1990). "Blood coagulation factors in human embryonic-fetal development: preferential expression of the FVII/tissue factor pathway". Blood. 76 (6): 1158–1164. doi:10.1182/blood.V76.6.1158.1158. PMID 1698100.
• Messier TL, Pittman DD, Long GL, Kaufman RJ, Church WR (March 1991). "Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X". Gene. 99 (2): 291–294. doi:10.1016/0378-1119(91)90141-W. PMID 1902434.
• Krishnaswamy S (March 1990). "Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation". The Journal of Biological Chemistry. 265 (7): 3708–3718. doi:10.1016/S0021-9258(19)39652-8. PMID 2303476.
• España F, Berrettini M, Griffin JH (August 1989). "Purification and characterization of plasma protein C inhibitor". Thrombosis Research. 55 (3): 369–384. doi:10.1016/0049-3848(89)90069-8. PMID 2551064.
• Fung MR, Hay CW, MacGillivray RT (June 1985). "Characterization of an almost full-length cDNA coding for human blood coagulation factor X". Proceedings of the National Academy of Sciences of the United States of America. 82 (11): 3591–3595. Bibcode:1985PNAS...82.3591F. doi:10.1073/pnas.82.11.3591. PMC 397831. PMID 2582420.
• Jagadeeswaran P, Reddy SV, Rao KJ, Hamsabhushanam K, Lyman G (December 1989). "Cloning and characterization of the 5' end (exon 1) of the gene encoding human factor X". Gene. 84 (2): 517–519. doi:10.1016/0378-1119(89)90529-5. PMID 2612918.
• Reddy SV, Zhou ZQ, Rao KJ, Scott JP, Watzke H, High KA, et al. (October 1989). "Molecular characterization of human factor XSan Antonio". Blood. 74 (5): 1486–1490. doi:10.1182/blood.V74.5.1486.1486. PMID 2790181.
• Kaul RK, Hildebrand B, Roberts S, Jagadeeswaran P (1986). "Isolation and characterization of human blood-coagulation factor X cDNA". Gene. 41 (2–3): 311–314. doi:10.1016/0378-1119(86)90112-5. PMID 3011603.
• Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP (February 1988). "The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action". Blood. 71 (2): 335–343. doi:10.1182/blood.V71.2.335.335. PMID 3422166.
• Gilgenkrantz S, Briquel ME, André E, Alexandre P, Jalbert P, Le Marec B, et al. (1986). "Structural genes of coagulation factors VII and X located on 13q34". Annales de Génétique. 29 (1): 32–35. PMID 3487272.
• Leytus SP, Foster DC, Kurachi K, Davie EW (September 1986). "Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C". Biochemistry. 25 (18): 5098–5102. doi:10.1021/bi00366a018. PMID 3768336.
• Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW (June 1984). "Characterization of a cDNA coding for human factor X". Proceedings of the National Academy of Sciences of the United States of America. 81 (12): 3699–3702. Bibcode:1984PNAS...81.3699L. doi:10.1073/pnas.81.12.3699. PMC 345286. PMID 6587384.
• McMullen BA, Fujikawa K, Kisiel W, Sasagawa T, Howald WN, Kwa EY, et al. (June 1983). "Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid". Biochemistry. 22 (12): 2875–2884. doi:10.1021/bi00281a016. PMID 6871167.
• Marchetti G, Castaman G, Pinotti M, Lunghi B, Di Iasio MG, Ruggieri M, et al. (August 1995). "Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain". British Journal of Haematology. 90 (4): 910–915. doi:10.1111/j.1365-2141.1995.tb05214.x. PMID 7669671. S2CID 29324903.
• Morgenstern KA, Sprecher C, Holth L, Foster D, Grant FJ, Ching A, et al. (March 1994). "Complementary DNA cloning and kinetic characterization of a novel intracellular serine proteinase inhibitor: mechanism of action with trypsin and factor Xa as model proteinases". Biochemistry. 33 (11): 3432–3441. doi:10.1021/bi00177a037. PMID 8136380.
• Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH (March 1994). "Protein S binds to and inhibits factor Xa". Proceedings of the National Academy of Sciences of the United States of America. 91 (7): 2728–2732. Bibcode:1994PNAS...91.2728H. doi:10.1073/pnas.91.7.2728. PMC 43443. PMID 8146182.
• Inoue K, Morita T (November 1993). "Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. The role of the carbohydrate moieties in the activation of factor X". European Journal of Biochemistry. 218 (1): 153–163. doi:10.1111/j.1432-1033.1993.tb18361.x. PMID 8243461.
• Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, et al. (August 1993). "Structure of human des(1-45) factor Xa at 2.2 A resolution". Journal of Molecular Biology. 232 (3): 947–966. doi:10.1006/jmbi.1993.1441. PMID 8355279.
• Sinha U, Wolf DL (February 1993). "Carbohydrate residues modulate the activation of coagulation factor X". The Journal of Biological Chemistry. 268 (5): 3048–3051. doi:10.1016/S0021-9258(18)53657-7. PMID 8428982.

Further reading

• Schwartz RA, Steen CJ, Gascon P, Schick P (18 March 2024). Talavera F, Sacher RA, Thiagarajan P (eds.). "Factor X Deficiency". MedScape. WebMD LLC.

External links

• "Summary for peptidase S01.216: coagulation factor Xa". MEROPS. European Molecular Biology Laboratory (EMBL).
• "Factor X deficiency". Canadian Hemophilia Society. 14 April 2018.